Compare YMT & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | SCNX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | China | United States |
| Employees | N/A | 19 |
| Industry | EDP Services | Other Pharmaceuticals |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | 19.0M |
| IPO Year | N/A | N/A |
| Metric | YMT | SCNX |
|---|---|---|
| Price | $0.87 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | ★ 319.3K | 314.3K |
| Earning Date | 06-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1,097.38 |
| Revenue Next Year | N/A | $239.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.12 | $0.24 |
| 52 Week High | $2.85 | $2.60 |
| Indicator | YMT | SCNX |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 39.06 |
| Support Level | $0.14 | $0.24 |
| Resistance Level | $1.90 | $0.48 |
| Average True Range (ATR) | 0.27 | 0.03 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 3.51 | 1.54 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.